- Home
- HYFM vs GDTC Comparison
HYFM vs GDTC Comparison
Compare HYFM & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYFM
- GDTC
- Stock Information
- Founded
- HYFM 1977
- GDTC 2018
- Country
- HYFM United States
- GDTC Singapore
- Employees
- HYFM N/A
- GDTC N/A
- Industry
- HYFM Industrial Machinery/Components
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- HYFM Industrials
- GDTC Health Care
- Exchange
- HYFM Nasdaq
- GDTC Nasdaq
- Market Cap
- HYFM 38.1M
- GDTC 33.4M
- IPO Year
- HYFM 2020
- GDTC 2023
- Fundamental
- Price
- HYFM $0.61
- GDTC $2.56
- Analyst Decision
- HYFM Hold
- GDTC Buy
- Analyst Count
- HYFM 2
- GDTC 1
- Target Price
- HYFM $0.70
- GDTC $5.00
- AVG Volume (30 Days)
- HYFM 168.0K
- GDTC 26.6K
- Earning Date
- HYFM 11-07-2024
- GDTC 01-01-0001
- Dividend Yield
- HYFM N/A
- GDTC N/A
- EPS Growth
- HYFM N/A
- GDTC N/A
- EPS
- HYFM N/A
- GDTC N/A
- Revenue
- HYFM $200,158,000.00
- GDTC $330,254.00
- Revenue This Year
- HYFM N/A
- GDTC $14.71
- Revenue Next Year
- HYFM $3.93
- GDTC N/A
- P/E Ratio
- HYFM N/A
- GDTC N/A
- Revenue Growth
- HYFM N/A
- GDTC N/A
- 52 Week Low
- HYFM $0.43
- GDTC $1.20
- 52 Week High
- HYFM $1.20
- GDTC $5.50
- Technical
- Relative Strength Index (RSI)
- HYFM 39.26
- GDTC 51.57
- Support Level
- HYFM $0.58
- GDTC $2.26
- Resistance Level
- HYFM $0.65
- GDTC $3.00
- Average True Range (ATR)
- HYFM 0.04
- GDTC 0.41
- MACD
- HYFM -0.02
- GDTC -0.04
- Stochastic Oscillator
- HYFM 11.06
- GDTC 27.85
About HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.